Our Perspectives
Cerberus Ventures partners with visionary founders and consequential companies looking to move the world forward.
No items found.
Oops! Something went wrong while submitting the form.
Why We Invested in Photon Queue
Photon Queue is working to build the next generation of quantum memory hardware.
Syntis Bio Reports Positive Initial Phase 1/1b Single Ascending Dose Data for SYNT-101, Supporting its Novel Approach to Obesity Treatment
SYNT-101 was well tolerated across all doses with no related GI adverse events, no serious adverse events, and no discontinuations.
Why We Invested in AquaPoro
Our investment in AquaPoro is underpinned by a belief that the next decade may require figuring out how to create more water.
AquaPoro Raises $5M to Advance Technology that Generates Net New Water from Air
AquaPoro's proprietary Atmospheric Low-humidity Moisture Adsorption (ALMA(TM)) technology extracts clean water from ambient air at lower energy and cost.
Our Investment in Layup Parts and Next-Gen Manufacturing
Layup Parts is building a different kind of factory.
The Future of Biosecurity with Red Queen Bio’s Hannu Rajaniemi
A discussion on the power of AI tools and their potential for scientific breakthroughs.
Backing Star Catcher and the First Power Grid for Space
Star Catcher is positioned to provide the missing piece: the world’s first power grid for space.
Star Catcher raises $65 million to build the first power grid in space
Cerberus' General John "Jay" Raymond to join the company's board.
PrismML Steps Out of Stealth
Most efficiency gains in AI are incremental. PrismML is going after something more fundamental.
PrismML Launches World's First 1-Bit AI Model to Redefine Intelligence at the Edge
PrismML, a pioneer in high-performance AI models, today emerged from stealth to introduce the world's first commercially viable 1-bit large language models, built on groundbreaking research developed at Caltech. PrismML's sweeping goal is to enable a future where powerful AI can run locally, efficiently, securely, and faster, and where datacenter buildouts can do more with fewer resources and avoid ballooning energy costs.
Announcing Our Investment in Virchow Medical
We’re proud to partner with Virchow to expand the availability of clinically-sourced genomic data.
Virchow Raises $4 Million to Advance Biopsy Specimen Stewardship and Expand Access to Precision Oncology
Cerberus Ventures leads financing alongside five physician users of Virchow’s biopsy technologies.
Why Now is the Time to Build in TechBio
Cerberus Ventures' Chenny Zhang joined a TechBio investor panel at the LSX Investival Showcase in Miami alongside a group of fellow investors to discuss the new era of tech-driven biology.
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions
Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the first patient has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery.
CES 2026: Quick Takes From the Floor
At CES 2026, we met with founders, operators, and platform builders across the technology ecosystem and here are a few quick takeaways.
The Year Ahead: Our 2026 Outlook
2025 was a year defined by rapid innovation and a shifting geopolitical landscape. Artificial intelligence advanced at breakneck speed, reshaping industries, economies, and even the foundations of society. The race toward harnessing artificial intelligence has become one of the defining competitions of our era.
No Results Found
Try adjusting your search
Footnotes
Disclaimer
Information included herein represents the views and beliefs of Cerberus. There can be no guarantee Cerberus Ventures will achieve its investment objectives or that partnering with Cerberus Ventures will ensure or contribute to the success of any company. Statements included herein are based upon information reasonably available to Cerberus as of the date included. However, the inclusion of such statements shall not create any implication that the information contained herein is correct in all respects, including as of any time subsequent to the date thereof, and Cerberus does not undertake any obligation to update such information at any time after such date. For more information about Cerberus, please visit www.cerberus.com.